This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prell, R. A. Articles by Jooss, K. Search for Related Content PubMed PubMed Citation Articles by Prell, R. A. Articles by Jooss, K.

Administration of IFN- Enhances the Efficacy of a Granulocyte Macrophage Colony Stimulating Factor–Secreting Tumor Cell Vaccine

Department of Preclinical Oncology and Immunology, Cell Genesys, Inc., South San Francisco, California

Requests for reprints: Karin Jooss, Cell Genesys Inc., Department of Preclinical Oncology and Immunology, 500 Forbes Blvd, South San Francisco, CA 94080. Phone: 650-266-2912; Fax: 650-266-3100; E-mail: Karin.jooss{at}cellgenesys.com.

IFN- is approved for the treatment of multiple cancers. Its pleiotropic properties include inhibition of proliferation and angiogenesis and induction of apoptosis. Type I IFNs also exert immunomodulatory effects, which make it an appropriate candidate to combine with cancer vaccines. The studies reported herein show that 50% of mice reject established B16 tumors following treatment with the combination of a granulocyte macrophage colony-stimulating factor–secreting tumor cell vaccine (B16.GM) and subclinical doses of recombinant murine IFN- delivered at the vaccine site. Similarly, 80% of mice treated with the combination reject established B16 tumors when recombinant murine IFN- is given at the challenge site, suggesting that in the latter case its antiproliferative, proapoptotic, and antiangiogenic properties may be involved in controlling tumor growth. In contrast, fewer than 10% of mice reject the tumors when either one is used as a monotherapy. Furthermore, a 30-fold increase in the frequency of melanoma-associated antigen (Trp-2 and gp100) specific T cells was observed in mice treated with the combination when compared with unvaccinated controls. These data show that IFN- combined with a granulocyte macrophage colony-stimulating factor–secreting tumor cell vaccine significantly enhances vaccine potency and may represent a potential new approach for tumor immunotherapy.

Key Words: GM-CSF • IFN- • cancer vaccine • immunotherapy • cytokines

This article has been cited by other articles:

				A. G. Sikora, N. Jaffarzad, Y. Hailemichael, A. Gelbard, S. W. Stonier, K. S. Schluns, L. Frasca, Y. Lou, C. Liu, H. A. Andersson, et al. IFN-{alpha} Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity J. Immunol., June 15, 2009; 182(12): 7398 - 7407. [Abstract] [Full Text] [PDF]

				K. W. Hance, C. J. Rogers, D. A. Zaharoff, D. Canter, J. Schlom, and J. W. Greiner The Antitumor and Immunoadjuvant Effects of IFN-{alpha} in Combination with Recombinant Poxvirus Vaccines Clin. Cancer Res., April 1, 2009; 15(7): 2387 - 2396. [Abstract] [Full Text] [PDF]